Ixazomib is an orally active proteasome inhibitor and there is little doubt that the TOURMALINE data show that it, in combination with Revlimid and dexmethasone in relapsed/refractory multiple myeloma is efficacious. And in terms of treatment delivery, we’ve seen that there really has been a large move towards using ixazomib during the COVID pandemic because it’s meant patients haven’t got to come into hospital, it’s meant they haven’t had to wait for an outpatient slot for their treatment, and yet we’ve still got an effective therapy...
Ixazomib is an orally active proteasome inhibitor and there is little doubt that the TOURMALINE data show that it, in combination with Revlimid and dexmethasone in relapsed/refractory multiple myeloma is efficacious. And in terms of treatment delivery, we’ve seen that there really has been a large move towards using ixazomib during the COVID pandemic because it’s meant patients haven’t got to come into hospital, it’s meant they haven’t had to wait for an outpatient slot for their treatment, and yet we’ve still got an effective therapy. And again, one of the things I think the pandemic has taught us is that patient time is an important gift we can give back to them. And so, the advantages of an oral a